Pharmafile Logo

Access and elimination: the future of DAAs in hepatitis C

January 25, 2017 | HCV, Pharmaphorum, hepatitis C 

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 

The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

http://www.researchpartnership.com/news/2017/01/access-and-elimination-the-future-of-daas-in-hepatit…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Webcast: Going for growth – Maximising your return on insights in Emerging Markets

Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Healthcare market research in emerging...

20 questions: Round 6

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month we asked our employees about office life in Singapore.Watch the video: https://www.researchpartnership.com/news/2017/09/20-questions-round-6/

Ageing Asia: What does this mean for the future of healthcare?

Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing...

Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations

Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging - one camp are proponents of the 'behavioural' segmentation based on secondary sales,...

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and...

PMRC EU, Düsseldorf 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 24-25 October in Düsseldorf, GermanyDirector, Anne Cunningham, and Associate Director, Nicky Barclay-Prout, are representing...

Device Attribute Testing

Our client wanted to determine the optimal new blood glucose monitoring device – one that would best retain their current customers and also attract new ones.  They also wanted to...

Research Partnership welcomes 20 new Graduates

This year we are celebrating 20 years in business and as part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 3...

Corporate Equity Survey

Our client’s senior management wanted to assess its company’s image amongst their key HCP stakeholders. The client wanted to measure familiarity and perceptions of the company versus its competitors, particularly...

Webcast: Capturing the “moments-of-truth” using online communities and bulletin boards

MROCs and bulletin boards are growing in popularity because they offer specific benefits over or alongside more traditional methodologies – providing the opportunity to create a panel of geographically disperse...